Glycopyrrolate was first approved by the U.S. Food and Drug Administration (FDA) on December 12, 1977. It has been available for medical use since then and has been prescribed for various indications over the years.

Glycopyrrolate is used to reduce excessive saliva and secretions, manage drooling, treat chronic obstructive pulmonary disease (COPD), and alleviate symptoms of gastrointestinal disorders such as irritable bowel syndrome (IBS).

Glycopyrrolate is typically available in oral tablet or injectable form. The dosage and administration instructions may vary depending on the specific condition being treated and individual factors. It is important to follow the instructions provided by the healthcare professional or the medication's label. Generally, the tablets are taken orally with or without food, as directed by the doctor.

One common side effect of glycopyrrolate is dry mouth, also known as xerostomia. Its anticholinergic properties can reduce saliva production, leading to a dry and uncomfortable sensation in the mouth. This side effect can cause difficulty in speaking, swallowing, and tasting, as well as an increased risk of dental problems. To mitigate dry mouth, it is recommended to stay hydrated, practice good oral hygiene, use saliva substitutes or sugar-free candies, and inform your dentist about your medication use to receive appropriate care.

Glycopyrrolate carries several important warnings and precautions. It should be used with caution in individuals with glaucoma, gastrointestinal disorders, urinary retention, cardiovascular disorders, and heat stroke risk. The medication can cause CNS effects, including drowsiness and blurred vision, which may impair driving and operating machinery. Special caution is advised in individuals with renal or hepatic impairment, during pregnancy and breastfeeding, and when considering potential drug interactions. Its systemic absorption and potential for withdrawal symptoms upon discontinuation should also be considered.

Before using glycopyrrolate, inform your healthcare professional about any known allergies, glaucoma, gastrointestinal disorders, urinary retention, cardiovascular conditions, heat stroke risk, renal or hepatic impairment, pregnancy, breastfeeding, and all medications or supplements you are taking. Exercise caution when driving or operating machinery due to potential CNS effects. Be aware of the possibility of systemic absorption and withdrawal symptoms upon discontinuation. Regular monitoring and consultation with a healthcare professional are important for personalized guidance and to ensure the safe and effective use of glycopyrrolate.

If you have been prescribed glycopyrrolate or any other medication, it is crucial to follow your healthcare professional's instructions and guidance. Be sure to take the medication as prescribed, adhere to the recommended dosage, and follow any specific instructions for administration. It is important to communicate openly with your healthcare provider about any concerns, questions, or changes in your condition. Additionally, be vigilant about any potential side effects and promptly report them to your healthcare professional. Precautions should be taken when using this medication in patients with liver or kidney impairment, as dosage adjustments or special monitoring may be required. The elderly population may be more sensitive to this medication's effects, and a specialist should determine pediatric use considering the child's specific condition. Pregnant and breastfeeding individuals should consult with healthcare professionals before using this medication. By maintaining good communication and staying informed, you can actively participate in your healthcare and contribute to your overall well-being.

1. SteriMax Inc., [Revised on 9th Mar 2018] [Accessed on 17th July 2023], https://pdf.hres.ca/dpd_pm/00044183.PDF
2. Apotex Inc., [Revised on Aug 2018] [Accessed on 17th July 2023], https://www1.apotex.com/products/us/downloads/pre/glyc_inj_ins.pdf
3. Jin Hye Min, et al., Effects of glycopyrrolate premedication on preventing postoperative catheter-related bladder discomfort in patients receiving ureteroscopic removal of ureter stone, Korean J Anesthesiol, 2016, 69(6): 563-567, [Accessed on 17th July 2023], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133226/pdf/kjae-69-563.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.